Doctor conflict disclosures put on hold; Teva to fight Dr. Reddy's on Copaxone generic; Roche benefits from U.K. cancer fund;

@FiercePharma: Top in FierceVaccines Thursday: Sanofi dengue vaccine filings could come as soon as next year's Q1, CEO says. Article | Follow @FiercePharma

@EricPFierce: Instead of buying counterfeit Viagra from China, this guy bought APIs and whipped up an ED drug in his home lab. Green Bay Press Gazette story | Follow @EricPFierce

@CarlyHFierce: ICYMI: This week's issue of FierceVaccines. Like it? Subscribe here free. | Follow @CarlyHFierce

> The Centers for Medicare and Medicaid Services is delaying the Sept. 30 public launch of the so-called doctors conflict of interest database after taking it offline to make fixes. Story

> U.K. pharma cost watchdog NICE is recommending use of Roche's ($RHHBY) Tarceva (erlotinib) as a second-line treatment in some cases of non-small cell lung cancer but no longer the use of AstraZeneca's ($AZN) Iressa (gefitinib). Story

> Teva Pharmaceutical Industries ($TEVA) has said it will defend against genericmaker Dr. Reddy's Laboratories' intent to make a generic of Teva's three-time-a-week version of Copaxone. Report

> Roche ($RHHBY) appears to be the biggest beneficiary of the U.K.'s Cancer Drug Fund. Story

Medical Device News

@FierceMedDev: Physicians hesitate to use HeartMate II pump after NEJM study, Thoratec down 30%. Story | Follow @FierceMedDev

@StacyALawrence: ICYMI: Scientist robot gets venture funding from Omega. Item | Follow @StacyALawrence

@VarunSaxena2: Elizabeth Pritts says her study's estimate of uterine sarcoma in morcellator patients will be 1:7450 morcellation. More | Follow @VarunSaxena2

@MichaelGFierce: Carnegie Mellon team creates self-assembling nanofibers for shaped delivery vehicles. More | Follow @MichaelGFierce

@EmilyWFierce: Boston Scientific subpoenaed by federal investigators over cardiology devices start-up. MassDevice story | Follow @EmilyWFierce

> Medtronic and Covidien face FTC pushback for pending merger. News

> GE-funded NGO aims to repair developed-world medical devices in the developing world. More

> Four unanswered questions about the looming LDT regulations. Item

Biotech News

@FierceBiotech: EuroBiotech report: Roche commits to Danish RNA lab, £3B London incubator hits go, Biotechs in post-IPO slump. Report | Follow @FierceBiotech

@JohnCFierce: Interesting fact, when DoD stopped $SRPT's work on Ebola, they left in a provision to reactivate the $291M contract. Story | Follow @JohnCFierce

@DamianFierce: Auris Medical prices $56M IPO, ushers in the era of $EARS on Wall Street. Release (PDF) | Follow @DamianFierce

> Astellas leans on U.K. luminaries for cancer R&D. More

> GlaxoSmithKline backs off from Galapagos' anti-inflammatory hopeful. News

> Tolero bags $14M to take its cancer drug to Phase III. Story

> FDA switches course on Tekmira drug as Ebola panic triggers policy review. Article

And Finally... Some medical apps that appear to have real health benefits carry the disclaimer that they are for "recreational purposes." Blog post

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.